<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80616">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01913847</url>
  </required_header>
  <id_info>
    <org_study_id>HM-SIL-301</org_study_id>
    <nct_id>NCT01913847</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension</brief_title>
  <official_title>Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and clinical efficacy of HGP1207
      (Sildenafil) in subjects with pulmonary hypertension associated with systolic heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in 6-min-walk test distance</measure>
    <time_frame>at 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 6-min-walk test distance</measure>
    <time_frame>at 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systolic pulmonary arterial pressure (PAP)</measure>
    <time_frame>at 6 weeks and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in [NT pro-BNP]</measure>
    <time_frame>at 6 weeks and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in NYHA functional class</measure>
    <time_frame>at 6 weeks and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) assessed by EuroQoL(EQ-5D-3L) and EQ visual analogue scales (VAS)</measure>
    <time_frame>at 6 weeks and 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delaying time to first occurrence of either cardiovascular events</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Systolic Dysfunction</condition>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Oral sildenafil 20 mg TID for 12 weeks</description>
    <arm_group_label>Sildenafil</arm_group_label>
    <other_name>HGP1207</other_name>
    <other_name>PAHTENSION chewable tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo TID for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of chronic heart failure (NYHA Class II and III)

          -  LVEF ≤ 40%

          -  Elevated systolic PAP: ≥ 40 mmHg

          -  Patients must be treated with an ACE inhibitor, ARB, beta-blocker, aldosterone
             antagonist at a stable dose for at least 4 weeks prior to visit 1

        Exclusion Criteria:

          -  Patients with pulmonary hypertension associated with chronic obstructive pulmonary
             disease, interstitial lung disease, chronic thromboembolism or unclear/multifactorial
             mechanisms

          -  Patients who have received Nitrates/NO donor or Cytochrome P450 3A4 inhibitors within
             30 days prior to visit 1

          -  Patients who have received calcium channel blocker, endothelin receptor antagonist,
             prostacyclin analogues, phosphodiesterase 5 inhibitors within 90 days prior to visit
             1

          -  History of hypersensitivity or allergy to sildenafil or any excipients of its
             formulation

          -  Patients with hypertension (sitSBP &gt;170 mmHg or sitDBP&gt;100 mmHg) or hypotension
             (sitSBP&lt;90 mmHg or sitDBP&lt;50 mmHg)

          -  Patients with other medical condition (i.e.,alcoholism, drug abuse) that may cause
             the patient to be non-compliant with the protocol, confound the data interpretation

          -  Pregnant females or those of child bearing potential who have not had a negative
             pregnancy test
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu Hyung Ryu, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Dongtan Sacred Heart Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kwon</last_name>
    <email>freedude@hanmi.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Han</last_name>
    <email>hanhs@hanmi.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>11 institutions including Hallym University Dongtan Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ok</last_name>
      <phone>82-31-8086-2538</phone>
      <email>sokei@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Kyu Hyung Ryu, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 30, 2013</lastchanged_date>
  <firstreceived_date>July 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sildenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
